S

Synlogic
D

SYBX

1.55000
USD
0.23
(17.42%)
مغلق
حجم التداول
0
الربح لكل سهم
-7
العائد الربحي
-
P/E
7
حجم السوق
18,128,969
أصول ذات صلة
A
ACAD
0.540
(2.45%)
22.560 USD
C
CRSP
2.460
(4.67%)
55.150 USD
E
EDIT
0.09500
(3.46%)
2.84000 USD
F
FATE
-0.01000
(-0.88%)
1.13000 USD
INCY
INCY
0.965
(1.41%)
69.250 USD
REGN
REGN
-0.78
(-0.14%)
547.35 USD
S
SAGE
-0.03500
(-0.38%)
9.13500 USD
S
SGMO
-0.00010
(-0.02%)
0.48010 USD
VRTX
VRTX
5.82
(1.25%)
469.72 USD
المزيد
الأخبار المقالات

العنوان: Synlogic

القطاع: Healthcare
الصناعة: Biotechnology
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformativetreatments for serious diseases.